Related Experiment Video

Updated: May 25, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Cardio-oncology: a new medical issue

D Cardinale1, A Colombo, G Lamantia

  • 1Cardiology Unit and Laboratory Medicine Unit, European Institute of Oncology, IRCCS, 20141 Milan, Italy. daniela.cardinale@ieo.it

Ecancermedicalscience
|January 26, 2012
PubMed

Insights

Cardio-oncology addresses the growing need for managing cancer patients with heart conditions. This field focuses on preventing, diagnosing, and treating heart problems arising from cancer and its treatments.

Area of Science:

  • Cardiology
  • Oncology
  • Cardio-oncology

Background:

  • Increasing numbers of cancer survivors and aging populations lead to more patients with co-existing cancer and cardiovascular diseases.
  • Cancer treatments can increase the risk of developing cardiovascular problems, necessitating specialized management.
  • A growing patient population requires integrated care to optimize treatment and preserve therapeutic options.

Purpose of the Study:

  • To establish a new discipline, cardio-oncology, to manage patients with cancer and cardiovascular co-morbidities.
  • To investigate novel strategies and gather evidence-based indications for managing these complex patients.
  • To foster interdisciplinary expertise for comprehensive patient care.

Main Methods:

  • Focus on early diagnosis of cardiotoxicity.
  • Implementing risk stratification and preventive measures.
  • Developing effective treatment and monitoring protocols for cardiotoxicity.

Main Results:

  • Cardio-oncology provides a framework for addressing the complex needs of cancer patients with cardiac issues.
  • The discipline aims to improve patient outcomes by integrating cardiac care into oncology.
  • Research and clinical practice are evolving to meet the challenges of cardiotoxicity.

Conclusions:

  • Cardio-oncology is essential for managing the rising incidence of cancer and cardiovascular co-morbidities.
  • This interdisciplinary field is crucial for optimizing treatment and preventing adverse cardiovascular events in cancer patients.
  • Further development of strategies for diagnosis, prevention, and treatment of cardiotoxicity is ongoing.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...